Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 7/20 | 0.61 |
| ▸ | DRD2 | P14416 | 6/20 | 0.61 |
| ▸ | DRD3 | P35462 | 6/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | HTR7 | P34969 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4252223 | 0.93 | POLB (0.68) | DRD4DRD2DRD3POLBNPSR1 | |
| SCHEMBL4247969 | 0.91 | ALDH1A1 (0.57) | DRD4DRD2DRD3POLBNPSR1 | |
| SCHEMBL4250371 | 0.89 | HTR7 (0.65) | DRD4DRD2DRD3ALDH1A1KDM4E | |
| SCHEMBL4254706 | 0.81 | MAPK1 (0.67) | DRD4DRD2DRD3POLBNPSR1 | |
| SCHEMBL4251913 | 0.81 | HTR7 (0.67) | DRD4DRD2DRD3ALDH1A1KDM4E | |
| SCHEMBL15937912 | 0.80 | HTR7 (0.77) | DRD4DRD2DRD3ALDH1A1KDM4E | |
| SCHEMBL29764250 | 0.80 | HTR7 (0.77) | DRD4DRD2DRD3ALDH1A1KDM4E | |
| SCHEMBL4242887 | 0.77 | DRD4 (0.55) | DRD4DRD2DRD3POLBNPSR1 | |
| SCHEMBL4254056 | 0.77 | DRD4 (0.56) | DRD4DRD2DRD3POLBNPSR1 | |
| SCHEMBL31010276 | 0.75 | CYP2D6 (0.48) | ALDH1A1KDM4EKMT2AMEN1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090306039-A1 | COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS | IRM LLC (BM) | 2009-12-10 | — | — | US | disclosed |
| CN-101490010-A | Compounds and compositions as ITPKB inhibitors | IRM LLC (VG) | 2009-07-22 | — | — | CN | disclosed |
| EP-2057124-A2 | COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS | IRM, LLC (BM) | 2009-05-13 | — | — | EP | disclosed |
| WO-2008011611-A2 | COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS | IRM LLC (BM) | 2008-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306039-A1 | COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS | IP6K1, IP6K2, IP6K3 | DRD4 4818/4885DRD2 4806/4885DRD3 4698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.